Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

West Pharmaceutical (WST) delivered earnings and revenue surprises of 27.34% and 8.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Q4 Earnings and Revenues Beat Estimates

- Conference Call Scheduled for 9 a.m. EST Today - EXTON, Pa.

West Announces Fourth-Quarter and Full-Year 2022 Results

West Pharmaceutical (WST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why West Pharmaceutical (WST) Might Surprise This Earnings Season

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: West Pharmaceutical Services (WST) Q4 Earnings Expected to Decline

The health care industry has several strong tailwinds, especially among companies active in international markets. Wealth is increasing in most of the world, and that means increasing demand for health services.

Could West Pharmaceutical Be a Value Stock?

Corning

West Ready Pack™ with Corning Valor® RTU Vials utilizing Stevanato Group's EZ-fill® technology EXTON, Pa. , Feb. 8, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announces the expansion of its landmark collaboration with Corning Incorporated (NYSE: GLW), that now includes the exclusive distribution rights for Corning Valor® Glass vials and the launch of its first product, West Ready Pack™ with Corning Valor® RTU Vials utilizing SG EZ-fill® technology.

West Expands Corning Collaboration and Launches First Product

EXTON, Pa., Feb. 2, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2022 financial results before the market opens on Thursday, February 16, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host Fourth-Quarter and Full-Year 2022 Conference Call and Announces Participation in Upcoming Investor Conferences

Product introductions and expert presentations offer thought leadership in drug delivery innovation and patient adherence to meet the challenges of pharmaceutical pipelines EXTON, Pa. , Jan. 31, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation at Pharmapack Europe 2023 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment.

West Announces Three New Product Innovations at Pharmapack Europe

Automatic Data Processing

Clorox

Ecolab

Essex Property Trust

W.W. Grainger

Lowe's

Medtronic

McCormick

Realty Income Corp

PPG Industries

Sherwin-Williams

Stanley Black & Decker

Sysco

T. Rowe Price Group

V.F.

Walgreens

NOBL fell 4.12% in December, which brings the Fund's return for the year to a loss of 6.5%. Thus far this month, through January 25th, the dividend aristocrat ETF is up 1.92% and starting the year on a bright note.

My Best Dividend Aristocrats For February 2023

Adobe

Autodesk

Amazon

Bank of America

Comcast

CME Group

Salesforce

Fortinet

Alphabet

Lam Research

Masco

Microchip Technology

MarketAxess Holdings

Monolithic Power Systems

ServiceNow

Palo Alto Networks

Polaris

Teradyne

U.S. Bancorp

Workday

Wells Fargo

Western Union

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

U.S. Wide-Moat Stocks On Sale: The January 2023 Heat Map

Albemarle

Nucor

Pentair

Target

NOBL gained 7.12% in November, which brings the Fund's return for the year to a loss of 2.14%. Thus far this month, through December 23rd, the dividend aristocrat ETF is down 3.47%, bringing its year-to-date return to -5.86%.

My Best Dividend Aristocrats For January 2023

EXTON, Pa. , Dec. 13, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announces that the Company's Board of Directors has approved a first-quarter 2023 dividend of $0.19 per share. The dividend will be paid on February 1, 2023, to shareholders of record as of January 25, 2023.

West Announces First-Quarter 2023 Dividend and Participation in Upcoming Investor Conference

BeiGene

Bio-Rad Laboratories

Catalent

DexCom

Edwards Lifesciences

Gilead Sciences

Intuitive Surgical

Moderna

Seagen

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

ProShares S&P 500 Dividend Aristocrats ETF

Roper Technologies

NOBL gained 10.31% in October, which brings the Fund's return for the year to a loss of 8.96%. Thus far this month, through November 22nd, the dividend aristocrat ETF is up 6.52%, bringing its year-to-date return to -3.03%.

My Best Dividend Aristocrats For December 2022

Brown & Brown

Church & Dwight

Enterprise Products Partners

Expeditors International of Washington

Next year isn't very far away. In less than two months, we'll be ringing in the New Year and making resolutions.

7 Dividend Stocks Set to Surge Higher in 2023

American Electric Power Company

Community Healthcare Trust

Emerson Electric

Entergy

First Interstate BancSystem

Honeywell

Heartland Financial USA

Rockwell Automation

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 8.8% and a median increase of 5.8%.

14 Upcoming Dividend Increases Including A Dividend King

News for West Pharmaceutical Services Stock (WST)